A5044564476- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Risks and Factors
- Nutrition and Health in Aging
- Head and Neck Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Lung Cancer Research Studies
- Cancer survivorship and care
- Family Support in Illness
- Gastric Cancer Management and Outcomes
- Frailty in Older Adults
- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Reproductive Biology and Fertility
- Smoking Behavior and Cessation
- Forecasting Techniques and Applications
- Acute Lymphoblastic Leukemia research
- PI3K/AKT/mTOR signaling in cancer
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Breast Cancer Treatment Studies
- Nutritional Studies and Diet
Dana-Farber Cancer Institute
2013-2024
ECOG-ACRIN Cancer Research Group
2020-2024
Centre Jean Perrin
2021
John Wiley & Sons (United States)
2016
Fred Hutch Cancer Center
2016
University of Washington Medical Center
2016
Cancer Research Center
2016
Boston University
2013
PURPOSE Despite defined grades of 1 to 5 for adverse events (AEs) on the basis Common Terminology Criteria Adverse Events criteria, mild (G1) and moderate (G2) AEs are often not reported in phase III trials. This under-reporting may inhibit our ability understand patient toxicity burden. We analyze relationship between experienced with side-effect bother treatment discontinuation . METHODS analyzed a Eastern Cooperative Oncology Group-American College Radiology Imaging Network trial...
Importance There is substantial interest in capturing cancer treatment tolerability from the patient’s perspective using patient-reported outcomes (PROs). Objective To examine whether a PRO question, item 5 Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale (GP5), was associated with early discontinuation (ETD) due to adverse events. Design, Setting, and Participants This prospective survey study conducted February April 2023. Among participants ECOG-ACRIN E1A11...
Central nervous system (CNS) involvement in patients with newly diagnosed acute myeloid leukemia (AML) is rare, and systematic data regarding outcome are scarce. This retrospective study summarized from 11 consecutive Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) clinical trials for AML. In all, 3240 AML were analyzed, 36 (1.11%) found to have CNS at diagnosis. The incidence disease among the 5 studies per protocol mandatory lumbar puncture...
Abstract The objective of this study is to examine the association between neighborhood socioeconomic status (nSES) and baseline allostatic load (AL) clinical trial endpoints in patients enrolled E1A11 therapeutic multiple myeloma (MM). Study were symptom burden (pain, fatigue, bother) at 5.5 months, non-completion induction therapy, overall survival (OS) progression-free (PFS). Multivariable logistic Cox regression examined associations nSES, AL patient outcomes. A 1-unit increase was...
5566 Background: Human papillomavirus (HPV) infection is now recognized as a risk factor of oropharyngeal squamous cell carcinoma (OPSCC) and approximately 60% OPSCC are HPV positive (+). ECOG 2399 using induction chemotherapy (IC) followed by chemoradiation demonstrated significantly improved 2-yr progression-free survival (PFS; 85% vs. 50%, p=0.05) overall (OS; 94% 58%p=0.004). These results have generated interest in development less toxic regimens for HPV(+) patients with lower dose...
PURPOSE To identify factors that may influence physician participation in tumor profiling studies and to assess the routine use of clinical practice. METHODS Physicians National Cancer Institute–Molecular Analysis for Therapy Choice (NCI-MATCH) were invited participate an electronic survey consisting 73 questions related genomic studies, practices education during usual patient care, background practice characteristics. RESULTS The response rate was 8.9% (171 surveys returned 1,931 sent). A...
Relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) lymphoma (LL) remains a therapeutic challenge. Preclinical data in both B- and T-ALL suggests synergy of venetoclax (VEN) with vincristine (VCR). We designed phase I/II trial (EA9152) the combination L-VCR VEN for patients r/r B-or T-cell ALL LL. Here, we report safety efficacy outcomes I portion this (NCT03504644).
Abstract Background: While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) dual cigarettes/ATPs are rising. Little is known about ATP patterns in cancer survivors enrolled clinical trials. We investigated prevalence product use, factors associated with past 30-day patients national Methods: Cancer (N = 756) 9 ECOG-ACRIN trials (2017–2021) completed a modified Patient Tobacco Use...
6028 Background: Abnormalities in EGFR signaling targets are associated with C resistance but no biomarker of has been identified HNSCC. We hypothesized that cases loss PTEN protein expression (PTEN null) or PIK3CA mutation would display Methods: E5397 was a phase III trial CDDP plus P and enrolled 117 eligible evaluable pts. were analyzed for 52 67 consented pts, respectively. Cell Signaling Technology, Cat. 9559) determined by automated quantitative analysis (AQUA) on the PM-2000 (HistoRx,...
Symptom monitoring is attracting attention as a way to improve adherence cancer therapy, reduce treatment-related toxicities, and possibly overall survival. How reporting thresholds affect symptom alert generation clinical outcomes poorly understood.
e19136 Background: Patient reported side effect bother is needed to understand tolerability of cancer drugs. We examined whether increase in from baseline cycle 7 as measured by a single item (GP5) the FACT-G, “I am bothered effects treatment”, was associated with early treatment discontinuation (ETD) multiple myeloma (MM) trial. Methods: Data were drawn induction phase ECOG ACRIN E1A06, two arm, 3 trial conducted patients untreated MM. The occurred over twelve, 28-day cycles. GP5 assessed...
Abstract Background Patients with advanced head and neck cancer have identified pain, fatigue, difficulties swallowing, breathing, communicating as high‐priority disease‐related symptoms. The Functional Assessment of Cancer Therapy‐Head Neck Symptom Index‐10 (FHNSI‐10) assesses these We sought to validate the FHNSI‐10, another brief symptom index (FHNSI‐7), individual endpoints representing high‐rated priority disease symptoms among patients recurrent or metastatic squamous cell carcinoma...
6016 Background: A germline mutation in let-7 complementary site 6 (LCS6) within the KRAS 3'-untranslated region (rs61764370, KRAS-variant: TG/GG) is known to associate with poor outcome and drug resistance various cancers compared wild type allele (TT). We examine prognostic significance of KRAS-variant recurrent/metastatic (R/M) head neck squamous cell carcinoma (HNSCC). Methods: The was determined 116 tumor DNA samples from HNSCC patients enrolled 3 clinical trials a tissue collection...
11123 Background: For the 10% of women diagnosed with cancer in reproductive age, health (RH) is a critical component oncologic survivorship. RH includes oncocontraception (OC), oncofertility (OF) and sexuality. Guidelines segregate these components resulting fragmented care management. Methods: The EROS trial clustered randomized performed at 17 NCI Community Oncology Research Program (NCORP) sites (including 8 NCORP 9 Minority/Underserved sites) from 2016-2023. Eligible subjects included...
11124 Background: The average recruitment of minority subjects in oncology trials is 4%. ECOG-ACRIN EROS trial was designed to be inclusive by inviting Minority/Underserved NCI Community Oncology Research Program (MU-NCORP) sites first, with remaining fulfilled NCORP sites. Our objective examine if the study recruited more than 4% patients, and MU-NCORP provided higher rates Methods: a clustered randomized performed at 17 (NCORP) (including 8 9 sites) from 2016-2023. Eligible included...
e23197 Background: Cancer diagnosis and therapeutic interventions are associated with altered reproductive health including sexuality. Despite pertinence to quality of life, cancer management frequently precludes periodic assessments sexual health. Methods: The EROS trial is a clustered randomized performed at 17 NCI Community Oncology Research Program (NCORP) sites (including 8 NCORP 9 Minority/Underserved sites) from 2016-2023. Eligible subjects included reproductively capable women aged...